Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Trulicity® (dulaglutide): REWIND Baseline Characteristics

In the REWIND study a total of 9901 patients in 24 countries were randomized. The average age was 66.2 years and the average HbA1c was 7.3 %. Around 1/3 had prior CVD, so most of the participants did not have previous CV disease or a previous CV event.


Detailed Information

The REWIND study was an event-driven, randomized, double-blind, phase 3 CV outcomes study of dulaglutide.1

The study evaluated the effect on MACE-3 and other serious outcomes with once-weekly dulaglutide 1.5 mg treatment compared with placebo when added to standard of care in participants 50 years of age and older with T2DM and established CV disease and/or risk factors.1

Eligible patients had

Age-Specific Inclusion Criteria for REWIND Trial1

If the participant's age was... 

Then they had to have... 

50-54 y

established CVD. 

55-59 y

established CVD or evidence of other subclinical CVD. 

60 y or older

established CVD, evidence of other subclinical CVD, or at least 2 other CV risk factors.

Abbreviations: CV = cardiovascular; CVD = cardiovascular disease; REWIND = Researching cardiovascular Events with a Weekly INcretin in Diabetes.

Patients were excluded if they had

  • liver disease
  • a history of pancreatitis
  • gastric emptying abnormalities
  • an eGFR of less than 15 mL/min/1.73m2 or on dialysis
  • a coronary or cerebrovascular event in the last 2 months or plans to revascularize, or
  • history of medullary C-cell hyperplasia or medullary thyroid cancer.1,2

A total of 9901 patients in 24 countries were randomized.2

More detailed information on baseline characteristics is found in

Baseline Characteristics of Patients Randomized in the REWIND Study2

Clinical Characteristics



Age, y, mean (SD)

66.2 (6.5)

66.2 (6.5)

Females, n (%)

2306 (46.6)

2283 (46.1)

DM duration, y,  mean (SD)

10.5 (7.3)

10.6 (7.2)

HbA1c, %, mean (SD)

7.3 (1.1)

7.4 (1.1)

BMI, kg/m2, mean (SD)

32.3 (5.7)

32.3 (5.8)

BP, mmHg, mean (SD)

137.1 (16.6)/78.4 (9.8)

137.3 (17.0)/78.5 (9.9)

Pulse, beats/min, mean (SD)

71.4 (10.7)

71.6 (11.0)

Cholesterol, mmol/L [mg/dL],  Mean (SD)

4.52 (1.16) [174.79 (44.86)]

4.52 (1.16) [174.79 (44.86)]

LDL cholesterol, mmol/L [mg/dL],  Mean (SD)

2.56 (0.98) [98.99 (37.90)]

2.56 (0.98) [98.99 (37.90)]

HDL cholesterol, mmol/L [mg/dL],  Mean (SD)

1.18 (0.33) [45.63 (12.76)]

1.18 (0.36) [45.63 (13.92)]

Median triglycerides (IQR), mmol/L [mg/dL], Mean (SD)

1.60 (1.15-2.2) [141.72 (101.86-194.86)]

1.60 (1.20-2.25) [141.72 (106.29-199.30)]

eGFR<60 mL/min/1.73 m2, n (%)

1081 (21.8)

1118 (22.6)

Albuminuria, n (%)a

1707 (34.5)

1760 (35.5)

Prior CV disease b, n (%)

1560 (31.5)

1554 (31.4)

Prior hypertension, n (%)

4605 (93.0)

4619 (93.3)

Prior heart failure, n (%)

421 (8.5)

432 (8.7)

Prior diabetic retinopathy, n (%)

448 (9.1)

443 (8.9)

Current tobacco use, n (%)

694 (14.0)

713 (14.4)

Abbreviations: BMI = body mass index; BP = blood pressure; CV = cardiovascular; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; IQR = interquartile range; LDL = low-density lipoprotein; REWIND = Researching cardiovascular Events with a Weekly INcretin in Diabetes.

aUACR ≥30 mg/g

bMyocardial infarction, ischemic stroke,unstable angina with electrocardiogram changes, myocardial ischemia on imaging or stress test, or coronary, carotid,or peripheral revascularization.


1Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42-49.

2Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.


CV = cardiovascular

CVD = cardiovascular disease

eGFR = estimated glomerular filtration rate

HbA1c = glycated hemoglobin

MACE-3 = major adverse cardiovascular events (death due to cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)

REWIND = Researching cardiovascular Events with a Weekly INcretin in Diabetes

T2DM = type 2 diabetes mellitus

Date of Last Review: 02 March 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request